FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386326008> ?p ?o ?g. }

• W4386326008 endingPage "7" @default.
• W4386326008 startingPage "1" @default.
• W4386326008 abstract "Paclitaxel (P) is a standard second-line chemotherapy in the treatment of advanced gastric cancer. This study compared the clinical outcome of a paclitaxel plus raltitrexed (RP) regimen as second-line treatment in metastatic gastric cancer (MGC) patients.An open, randomized, multi-center phase II clinical trial was conducted involving 148 patients who were randomly assigned and treated with RP [raltitrexed (3 mg/m2 on day 1) and paclitaxel (135 mg/m2 on day 1 every 3 weeks)] or P [paclitaxel (135 mg/m2 on day 1 every 3 weeks)] as 2nd-line chemotherapy. The primary endpoint was progression-free survival (PFS). The secondary endpoints were the overall response rate (ORR), overall survival (OS), and safety.PFS had a tendency to be prolonged with RP compared to P (2.7 months vs. 1.7 months; P = 0.148). OS was also prolonged with RP compared to P (10.2 months vs. 6.1 months; P = 0.140). The ORR was equal in the RP and P groups (6.8% and 4.0%; P = 0.72). The disease control rate (DCR) in the RP and P groups was 56.2% and 36.0%, respectively. Grade 3-4 treatment-related adverse events occurred in 36.2% (RP) and 28.2% (P) of patients. Frequent grade 3-4 toxicities for RP and P were neutropenia (11.0% and 4.0%), anemia (1.4% and 4.0%), and thrombocytopenia (1.4% and 5.3%), and all grades of peripheral neurotoxicity (12.3% vs. 17.3%). All grades of hepatic toxicity were demonstrated for the RP and P groups based on elevated aminotransferase levels (27.4% and 14.1%). Subgroup analysis shows if MGC was combined with ascites or peritoneal involvement, the OS of the RP regimen was longer (P = 0.05).Second-line palliative chemotherapy with RP was shown to prolong the PFS and OS, especially among patients with ascites or peritoneal involvement, which warrants confirmation using larger sample studies." @default.
• W4386326008 created "2023-09-01" @default.
• W4386326008 creator A5001162052 @default.
• W4386326008 creator A5007875050 @default.
• W4386326008 creator A5013312078 @default.
• W4386326008 creator A5022387395 @default.
• W4386326008 creator A5024543012 @default.
• W4386326008 creator A5029322489 @default.
• W4386326008 creator A5052168680 @default.
• W4386326008 creator A5058433699 @default.
• W4386326008 creator A5072492963 @default.
• W4386326008 creator A5077558876 @default.
• W4386326008 creator A5078949281 @default.
• W4386326008 creator A5084985894 @default.
• W4386326008 date "2023-08-31" @default.
• W4386326008 modified "2023-10-13" @default.
• W4386326008 title "Comparing effectiveness and safety of paclitaxel plus raltitrexed vs. paclitaxel alone in second-line palliative chemotherapy for metastatic gastric adenocarcinoma: A randomized phase II clinical trial" @default.
• W4386326008 cites W1985233531 @default.
• W4386326008 cites W2002014955 @default.
• W4386326008 cites W2016626759 @default.
• W4386326008 cites W2042276392 @default.
• W4386326008 cites W2103588606 @default.
• W4386326008 cites W2104759721 @default.
• W4386326008 cites W2115984906 @default.
• W4386326008 cites W2292193857 @default.
• W4386326008 cites W2330265293 @default.
• W4386326008 cites W2439648601 @default.
• W4386326008 cites W2572709096 @default.
• W4386326008 cites W2603217543 @default.
• W4386326008 cites W2725137486 @default.
• W4386326008 cites W2738707880 @default.
• W4386326008 cites W2753382295 @default.
• W4386326008 cites W2788279585 @default.
• W4386326008 cites W2792686415 @default.
• W4386326008 cites W2809847023 @default.
• W4386326008 cites W2887115697 @default.
• W4386326008 cites W2888388350 @default.
• W4386326008 cites W3128558299 @default.
• W4386326008 cites W4211011108 @default.
• W4386326008 cites W4211130279 @default.
• W4386326008 cites W4214773926 @default.
• W4386326008 cites W4243365669 @default.
• W4386326008 doi "https://doi.org/10.20892/j.issn.2095-3941.2023.0112" @default.
• W4386326008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37653589" @default.
• W4386326008 hasPublicationYear "2023" @default.
• W4386326008 type Work @default.
• W4386326008 citedByCount "0" @default.
• W4386326008 crossrefType "journal-article" @default.
• W4386326008 hasAuthorship W4386326008A5001162052 @default.
• W4386326008 hasAuthorship W4386326008A5007875050 @default.
• W4386326008 hasAuthorship W4386326008A5013312078 @default.
• W4386326008 hasAuthorship W4386326008A5022387395 @default.
• W4386326008 hasAuthorship W4386326008A5024543012 @default.
• W4386326008 hasAuthorship W4386326008A5029322489 @default.
• W4386326008 hasAuthorship W4386326008A5052168680 @default.
• W4386326008 hasAuthorship W4386326008A5058433699 @default.
• W4386326008 hasAuthorship W4386326008A5072492963 @default.
• W4386326008 hasAuthorship W4386326008A5077558876 @default.
• W4386326008 hasAuthorship W4386326008A5078949281 @default.
• W4386326008 hasAuthorship W4386326008A5084985894 @default.
• W4386326008 hasBestOaLocation W43863260081 @default.
• W4386326008 hasConcept C121608353 @default.
• W4386326008 hasConcept C123321153 @default.
• W4386326008 hasConcept C126322002 @default.
• W4386326008 hasConcept C141071460 @default.
• W4386326008 hasConcept C143998085 @default.
• W4386326008 hasConcept C168563851 @default.
• W4386326008 hasConcept C197934379 @default.
• W4386326008 hasConcept C203092338 @default.
• W4386326008 hasConcept C2776694085 @default.
• W4386326008 hasConcept C2777063308 @default.
• W4386326008 hasConcept C2777292972 @default.
• W4386326008 hasConcept C2777299880 @default.
• W4386326008 hasConcept C2779268555 @default.
• W4386326008 hasConcept C2780456651 @default.
• W4386326008 hasConcept C2781413609 @default.
• W4386326008 hasConcept C71924100 @default.
• W4386326008 hasConcept C90924648 @default.
• W4386326008 hasConceptScore W4386326008C121608353 @default.
• W4386326008 hasConceptScore W4386326008C123321153 @default.
• W4386326008 hasConceptScore W4386326008C126322002 @default.
• W4386326008 hasConceptScore W4386326008C141071460 @default.
• W4386326008 hasConceptScore W4386326008C143998085 @default.
• W4386326008 hasConceptScore W4386326008C168563851 @default.
• W4386326008 hasConceptScore W4386326008C197934379 @default.
• W4386326008 hasConceptScore W4386326008C203092338 @default.
• W4386326008 hasConceptScore W4386326008C2776694085 @default.
• W4386326008 hasConceptScore W4386326008C2777063308 @default.
• W4386326008 hasConceptScore W4386326008C2777292972 @default.
• W4386326008 hasConceptScore W4386326008C2777299880 @default.
• W4386326008 hasConceptScore W4386326008C2779268555 @default.
• W4386326008 hasConceptScore W4386326008C2780456651 @default.
• W4386326008 hasConceptScore W4386326008C2781413609 @default.
• W4386326008 hasConceptScore W4386326008C71924100 @default.
• W4386326008 hasConceptScore W4386326008C90924648 @default.
• W4386326008 hasLocation W43863260081 @default.
• W4386326008 hasLocation W43863260082 @default.
• W4386326008 hasOpenAccess W4386326008 @default.

• next